Vaxcyte (PCVX) Change in Accured Expenses (2019 - 2026)

Vaxcyte (PCVX) has 8 years of Change in Accured Expenses data on file, last reported at -$15.0 million in Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at -$15.0 million, down 241.86% year-over-year; the trailing twelve-month figure through Mar 2026 was -$8.3 million (up 74.05% YoY), and the FY2025 annual result was $2.3 million, up 106.46% from the prior year.
• Change in Accured Expenses slipped to -$15.0 million in Q1 2026 per PCVX's latest filing, from $6.2 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $6.2 million in Q4 2025 and troughed at -$21.7 million in Q3 2024.
• A 5-year average of -$2.4 million and a median of -$737000.0 in 2022 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2023 and 2024: Change in Accured Expenses jumped 281.9% in 2023, then sank 1239.91% in 2024.
• A 5-year view of Change in Accured Expenses shows it stood at -$2.3 million in 2022, then jumped by 281.9% to $4.1 million in 2023, then sank by 325.59% to -$9.3 million in 2024, then jumped by 166.81% to $6.2 million in 2025, then plunged by 341.21% to -$15.0 million in 2026.
• Business Quant data shows PCVX's Change in Accured Expenses at -$15.0 million in Q1 2026, $6.2 million in Q4 2025, and -$2.5 million in Q3 2025.